DJ Affluent Medical announces the approval of its Registration Document by the French Financial Markets Authority (AMF) as part of its proposed IPO on the Euronext Paris regulated market. Affluent
April 13, 2021
Abdominal aortic aneurysm (AAA) patients who are 90 or older fare just as well as their younger counterparts after endovascular aneurysm repair (EVAR), a study shows.
After accounting for differences in comorbidity burden and other factors with propensity-score matching, 30-day mortality and major adverse event rates did not significantly differ between nonagenarians and patients from other age groups, lead author Carlota Fernandez Prendes, MD (Ludwig-Maximilians-University Hospital, Munich, Germany), and colleagues report.
The findings, published in the April 20, 2021, issue of the
Journal of the American College of Cardiology, were consistent in patients with either intact or ruptured aneurysms.
“Just using age as a [criterion] for intact and for ruptured aneurysms should not exclude patients from receiving treatment” with EVAR, Prendes told TCTMD. Instead, she and her co-authors recommend “tailored indications and carefully balanced risk assessment” to
Health tips from Dr. Oz and Dr. Roizen for 3-13-21
By Drs. Mehmet Oz and Mike Roizen 3 hours ago
Severe illness from COVID-19. What’s your risk?
NFTs, non-fungible tokens, are being used to sell (nonexistent or over-existent) digital art. For example, a digital video by Mike Winkelmann, AKA Beeple, sold for $6.6 million, but you can have precisely the same thing in your living room if you Google “Crossroad #1/1.” The art market is risky business, but it’s nothing compared to the chances most Americans are taking over 75 percent of U.S. adults are at risk for severe illness from COVID-19.
April 13, 2021
Patients presenting late to the hospital with STEMI fare “remarkably” worse than people who get to the hospital within the first 12 hours after symptom onset, but late presentation in and of itself does not independently predict worse outcomes, a large, retrospective analysis from Korea confirms.
However, the nationwide data also point to a steep decline in the use of invasive procedures as time to presentation lengthened, with investigators recording a strong, inverse relationship between use of invasive procedures and mortality.
“Inverse steep differences in the use of invasive interventional procedures and mortality rates were found between the first ( 12 hours) and the second (12 to 24 hours) symptom-to-door time 12-hour interval in STEMI patients presenting at 48 hours, indicating that the practice pattern of interventional procedures might affect the clinical outcomes of STEMI late presenters,” Kyung Hoon Cho, MD, PHD (Chonnam National University H
email article
One thing an SGLT2 won t do? Dapagliflozin (Farxiga) flopped for hospitalized COVID-19 patients in the phase III DARE-19 trial. Full results are coming at the American College of Cardiology meeting. (
Pharmaphorum)
Johnson & Johnson s COVID vaccine is now the center of attention for rare thrombotic events. (FDA)
Post-discharge anticoagulation for COVID-19 patients was associated with 46% lower risk of major thromboembolism or death in one hospital system s registry data. (
Blood)
Kaiser Health News.
Journal of the American College of Cardiology)
Medtronic has a class I recall out on Evera, Viva, Brava, Claria, Amplia, Compia, and Visia ICDs and CRT-Ds due to short circuiting that depletes the battery, sometimes in just 1 day, the FDA cautioned.